MD20180040A2 - Inhibitori ai virusului hepatic C - Google Patents

Inhibitori ai virusului hepatic C Download PDF

Info

Publication number
MD20180040A2
MD20180040A2 MDA20180040A MD20180040A MD20180040A2 MD 20180040 A2 MD20180040 A2 MD 20180040A2 MD A20180040 A MDA20180040 A MD A20180040A MD 20180040 A MD20180040 A MD 20180040A MD 20180040 A2 MD20180040 A2 MD 20180040A2
Authority
MD
Moldova
Prior art keywords
hepatitis
virus
inhibitors
relates
formulaas
Prior art date
Application number
MDA20180040A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Inventor
Кила Бьёрнсон
Эда Каналес
Джероми Дж. Коттелл
Капил Кумар Карки
Эшли Энн Катана
Дэррил Като
Тецуя Кобаяси
Джон О. Линк
Рубен Мартинес
Бартон В. Филлипс
Хюн-цзюн ПЮНЬ
Майкл Санджи
Адам Джеймс ШРАЙЕР
Дастин Сиджел
Джеймс Г. ТЕЙЛОР
Чинх Вьет Трен
Мартин Тереса Алехандра Трехо
Рэндолл В. ВИВЬЕН
Чжэн-Юй Ян
Джефф ЗАБЛОКИ
Шейла Зипфел
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48803614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20180040(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20180040A2 publication Critical patent/MD20180040A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MDA20180040A 2012-07-03 2013-07-02 Inhibitori ai virusului hepatic C MD20180040A2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US201361798524P 2013-03-15 2013-03-15
PCT/US2013/049119 WO2014008285A1 (en) 2012-07-03 2013-07-02 Inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
MD20180040A2 true MD20180040A2 (ro) 2018-11-30

Family

ID=48803614

Family Applications (2)

Application Number Title Priority Date Filing Date
MDA20180040A MD20180040A2 (ro) 2012-07-03 2013-07-02 Inhibitori ai virusului hepatic C
MDA20140136A MD4602B1 (ro) 2012-07-03 2013-07-02 Inhibitori ai virusului hepatic C

Family Applications After (1)

Application Number Title Priority Date Filing Date
MDA20140136A MD4602B1 (ro) 2012-07-03 2013-07-02 Inhibitori ai virusului hepatic C

Country Status (40)

Country Link
US (7) US20150175655A1 (2)
EP (4) EP3492464B1 (2)
JP (4) JP6025977B2 (2)
KR (3) KR102040023B1 (2)
CN (2) CN104540832B (2)
AP (1) AP3903A (2)
AR (1) AR091661A1 (2)
AU (6) AU2013286729B2 (2)
BR (2) BR112014033080B1 (2)
CA (1) CA2877005C (2)
CL (1) CL2014003634A1 (2)
CO (1) CO7160104A2 (2)
CR (1) CR20150045A (2)
CY (2) CY1118379T1 (2)
DK (2) DK2870160T3 (2)
EA (2) EA027390B1 (2)
EC (1) ECSP15002066A (2)
ES (3) ES2716138T3 (2)
HR (2) HRP20161379T1 (2)
HU (2) HUE032404T2 (2)
IL (4) IL236500B (2)
IN (1) IN2014MN02598A (2)
LT (2) LT3159345T (2)
MD (2) MD20180040A2 (2)
ME (2) ME02547B (2)
MX (2) MX360597B (2)
MY (1) MY173342A (2)
NZ (2) NZ739248A (2)
PE (1) PE20150204A1 (2)
PH (3) PH12014502862A1 (2)
PL (2) PL3159345T3 (2)
PT (2) PT3159345T (2)
RS (2) RS55494B1 (2)
SG (3) SG10201702950TA (2)
SI (2) SI3159345T1 (2)
SM (3) SMT201900167T1 (2)
TW (1) TWI602822B (2)
UA (1) UA119315C2 (2)
UY (1) UY34888A (2)
WO (1) WO2014008285A1 (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MX351816B (es) 2013-01-31 2017-10-30 Gilead Pharmasset Llc Formulacion de combinacion de dos compuestos antivirales.
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR102215400B1 (ko) 2013-03-15 2021-02-10 길리애드 사이언시즈, 인코포레이티드 C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
ES2724460T3 (es) * 2013-12-23 2019-09-11 Gilead Pharmasset Llc Síntesis de un tripéptido que inhíbe el NS3 del virus de VHC macrocíclico
AU2014370124A1 (en) 2013-12-23 2016-06-23 Gilead Sciences, Inc. Crystalline forms of a macrocyclic HCV NS3 inhibiting tripeptide
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
EP3939985B1 (en) 2014-12-26 2024-05-08 Emory University Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
CN107250097B (zh) * 2015-02-16 2020-08-07 中央硝子株式会社 含氟α-酮羧酸酯类的实用制造方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN120887906A (zh) 2016-05-10 2025-11-04 C4医药公司 用于靶蛋白降解的螺环降解决定子体
KR102202984B1 (ko) 2016-05-27 2021-01-13 길리애드 사이언시즈, 인코포레이티드 Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
JOP20170127A1 (ar) 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
EP3515910B1 (en) 2016-09-22 2020-07-15 Astrazeneca AB 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma
BR112019015886A2 (pt) * 2017-02-01 2020-03-17 Abbvie Inc. Processos enzimáticos para a preparação de ácido (±)-2-(difluorometil)-1-(alcoxicarbonil)-ciclopropanocarboxílico e (±)-ácido 2-(vinil)-1-(alcoxicarbonil)-ciclopropanocarboxílico
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911428B2 (en) 2000-12-12 2005-06-28 Schering Corporation Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
CA2465247C (en) 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US6878722B2 (en) 2002-05-20 2005-04-12 Bristol-Myers Squibb Company Substituted cycloalkyl P1′ hepatitis C virus inhibitors
EP1506172B1 (en) 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
ES2320771T3 (es) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
WO2004093798A2 (en) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
NZ544076A (en) 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20080311077A1 (en) 2004-07-16 2008-12-18 Kleem Chaudhary Antiviral Compounds
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
EA019888B1 (ru) 2005-07-25 2014-07-30 Интермьюн, Инк. Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
AU2006275605B2 (en) * 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
ATE493409T1 (de) 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2086982B1 (en) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
ES2444575T3 (es) 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
US20090155209A1 (en) 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
KR20100027134A (ko) 2007-05-10 2010-03-10 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
CA2691442C (en) 2007-06-29 2014-01-21 Gilead Sciences, Inc. Antiviral compounds
SG182979A1 (en) 2007-06-29 2012-08-30 Gilead Sciences Inc Antiviral compounds
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2700383A1 (en) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
WO2009055467A2 (en) 2007-10-24 2009-04-30 Virobay, Inc. Compounds that inhibit protease cathepsin s and hcv replication
WO2009055335A2 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
EP2222161A4 (en) 2007-12-05 2011-09-28 Enanta Pharm Inc QUINOXALINYL DERIVATIVES
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
KR101683559B1 (ko) 2007-12-21 2016-12-08 셀진 아빌로믹스 리서치, 인코포레이티드 Ｈｃｖ 프로테아제 억제제 및 이의 용도
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CA2713005A1 (en) 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Difluorinated tripeptides as hcv serine protease inhibitors
BRPI0908021A2 (pt) 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
WO2009108507A1 (en) 2008-02-25 2009-09-03 Merck & Co., Inc. Therapeutic compounds
WO2009114633A1 (en) 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
JP5490778B2 (ja) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
BRPI0916235B8 (pt) * 2008-07-22 2021-05-25 Merck Sharp & Dohme composto, composição farmacêutica, e, uso do composto ou da composição
BRPI0916609A2 (pt) 2008-08-07 2015-08-04 Hoffmann La Roche Processo para a preparação de um macrociclo
CA2734744A1 (en) 2008-08-20 2010-02-25 Michael Eissenstat Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
ES2474992T3 (es) 2008-09-16 2014-07-10 Boehringer Ingelheim International Gmbh Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de HCV
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
AP2011005695A0 (en) 2008-10-15 2011-06-30 Intermune Inc Therapeutic antiviral poptides.
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
EP2350114A1 (en) 2008-11-20 2011-08-03 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
DK2358355T3 (da) 2008-11-21 2013-12-16 Boehringer Ingelheim Int Farmaceutisk sammensætning af en potent HCV-inhibitor til oral indgivelse
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EA021794B1 (ru) 2008-12-10 2015-09-30 Ачиллион Фармасьютикалз, Инк. Циклические аналоги 4-амино-4-оксобутаноил пептидов, ингибиторы репликации вирусов
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102300871A (zh) 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
PL2382198T3 (pl) 2008-12-23 2013-11-29 Janssen Pharmaceuticals Inc Sposoby i półprodukty do otrzymywania makrocyklicznego inhibitora proteazy HCV
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
EP2432318A4 (en) 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
SG178043A1 (en) 2009-07-31 2012-03-29 Cadila Healthcare Ltd Substituted benzamide derivatives as glucokinase (gk) activators
CN102470158A (zh) 2009-08-27 2012-05-23 默沙东公司 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
WO2011038293A1 (en) 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
US20110082182A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
TW201119667A (en) 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
MY156888A (en) 2010-03-10 2016-04-15 Abbvie Bahamas Ltd Solid Compositions
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CA2801584A1 (en) 2010-06-07 2011-12-15 Abbvie Inc. Macrocyclic hepatitis c serine protease inhibitors
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
KR102163902B1 (ko) 2010-09-21 2020-10-12 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
US20130178413A1 (en) 2010-09-21 2013-07-11 John A. McCauley Hcv ns3 protease inhibitors
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
US20120101032A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
CN103717067A (zh) 2010-12-14 2014-04-09 默沙东公司 制备大环内酰胺的方法与中间体
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130129671A1 (en) 2011-05-27 2013-05-23 Bristol-Myers Squibb Company Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
US9238604B2 (en) 2011-08-19 2016-01-19 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
IN2014CN03113A (2) 2011-10-31 2015-07-03 Merck Sharp & Dohme
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
CN104244926A (zh) 2012-01-12 2014-12-24 勃林格殷格翰国际有限公司 作为强效的hcv 抑制剂的稳定的药物制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
KR102215400B1 (ko) 2013-03-15 2021-02-10 길리애드 사이언시즈, 인코포레이티드 C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제

Also Published As

Publication number Publication date
CO7160104A2 (es) 2015-01-15
JP2020143107A (ja) 2020-09-10
KR20160040743A (ko) 2016-04-14
TW201414740A (zh) 2014-04-16
EP2870160B1 (en) 2016-09-28
LT2870160T (lt) 2016-12-12
CN106117309B (zh) 2019-08-30
KR102040023B1 (ko) 2019-11-05
EP2870160A1 (en) 2015-05-13
EP3159345B1 (en) 2019-01-09
AR091661A1 (es) 2015-02-18
US10603318B2 (en) 2020-03-31
MD20140136A2 (ro) 2015-05-31
PH12020550552A1 (en) 2021-07-26
US10335409B2 (en) 2019-07-02
IL261581A (en) 2018-10-31
IL269662A (en) 2019-11-28
PL2870160T3 (pl) 2017-05-31
ES2605383T3 (es) 2017-03-14
EA201790661A3 (ru) 2017-10-31
JP6025977B2 (ja) 2016-11-16
CN104540832A (zh) 2015-04-22
AU2021204238A1 (en) 2021-07-22
JP2018154651A (ja) 2018-10-04
CA2877005A1 (en) 2014-01-09
WO2014008285A1 (en) 2014-01-09
US20140017198A1 (en) 2014-01-16
EP3825312A1 (en) 2021-05-26
HUE032404T2 (en) 2017-09-28
US20190008858A1 (en) 2019-01-10
SI2870160T1 (sl) 2016-11-30
CY1118379T1 (el) 2017-06-28
PH12014502862B1 (en) 2015-02-23
DK3159345T3 (en) 2019-03-25
EP3492464A1 (en) 2019-06-05
DK2870160T3 (en) 2017-01-23
ES2716138T3 (es) 2019-06-10
HRP20161379T1 (hr) 2016-12-02
JP2015523365A (ja) 2015-08-13
AU2016200670A1 (en) 2016-02-25
AU2013286729B2 (en) 2015-11-12
PE20150204A1 (es) 2015-02-12
RS55494B1 (sr) 2017-04-28
ME03362B (me) 2019-10-20
RS58409B1 (sr) 2019-04-30
EP3159345A1 (en) 2017-04-26
US20160130300A1 (en) 2016-05-12
SMT201600470B (it) 2017-03-08
SG11201408739VA (en) 2015-01-29
NZ703064A (en) 2016-12-23
AU2016200201A1 (en) 2016-02-04
PH12016502040A1 (en) 2019-02-27
SMT201900167T1 (it) 2019-05-10
AU2013286729A1 (en) 2015-01-22
EA027390B1 (ru) 2017-07-31
IL236500A0 (en) 2015-02-26
ECSP15002066A (es) 2015-11-30
AP3903A (en) 2016-11-17
AU2017203984A1 (en) 2017-07-06
UA119315C2 (uk) 2019-06-10
IN2014MN02598A (2) 2015-07-24
MX2014015846A (es) 2015-08-14
CA2877005C (en) 2016-12-13
BR122021012378B1 (pt) 2022-05-10
US20160361375A1 (en) 2016-12-15
PT2870160T (pt) 2016-12-12
AU2019222909A1 (en) 2019-09-19
CY1121418T1 (el) 2020-05-29
AU2019222909B2 (en) 2021-03-25
BR112014033080A2 (pt) 2017-06-27
UY34888A (es) 2014-01-31
HK1209416A1 (en) 2016-04-01
KR101610575B1 (ko) 2016-04-07
EA201492214A1 (ru) 2015-10-30
PH12014502862A1 (en) 2015-02-23
ME02547B (me) 2017-02-20
SG10201702950TA (en) 2017-06-29
EP3492464B1 (en) 2020-08-19
CL2014003634A1 (es) 2015-11-06
HK1210151A1 (en) 2016-04-15
PL3159345T3 (pl) 2019-09-30
HRP20190578T1 (hr) 2019-05-17
US9655944B2 (en) 2017-05-23
TWI602822B (zh) 2017-10-21
EA201790661A2 (ru) 2017-08-31
AP2014008166A0 (en) 2014-12-31
MX360597B (es) 2018-11-09
SI3159345T1 (sl) 2019-03-29
MX2018013668A (es) 2019-01-28
BR112014033080B1 (pt) 2022-03-29
IL261581B (en) 2019-10-31
CN106117309A (zh) 2016-11-16
US20150175655A1 (en) 2015-06-25
PT3159345T (pt) 2019-04-15
US20190365748A1 (en) 2019-12-05
CN104540832B (zh) 2016-08-24
KR20150034698A (ko) 2015-04-03
MY173342A (en) 2020-01-17
NZ739248A (en) 2019-05-31
JP2016041743A (ja) 2016-03-31
SG10201912269YA (en) 2020-02-27
ES2827300T3 (es) 2021-05-20
US9296782B2 (en) 2016-03-29
IL252446A0 (en) 2017-07-31
MD4602B1 (ro) 2018-11-30
SMT201600470T1 (it) 2017-03-08
AU2017203984B2 (en) 2019-06-06
CR20150045A (es) 2015-05-13
EA033961B1 (ru) 2019-12-13
US20170290827A1 (en) 2017-10-12
KR20190124346A (ko) 2019-11-04
IL236500B (en) 2018-02-28
HUE042345T2 (hu) 2019-06-28
LT3159345T (lt) 2019-03-12

Similar Documents

Publication Publication Date Title
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
PH12017501426A1 (en) Derivatives of betulin
IN2014MN02652A (2)
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12016500169A1 (en) Polymorph of syk inhibitors
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
IN2014CN04449A (2)
IN2014DN06964A (2)
DOP2014000250A (es) Nuevos compuestos de pirazol
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
IN2014DN06192A (2)
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
PT2812332T (pt) Métodos para a preparação do composto profármaco piperazina inibidor da conjugação ao vih
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
IN2014DN09451A (2)
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
WO2014125233A3 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
MX2013002656A (es) Nuevo proceso.
IN2013CN00515A (2)
IN2014DN07498A (2)
UA79385U (ru) Способ получения производных (((2-r-1,3-тиазол- 4-ил)метил)сульфанил)-азолов
UA79386U (ru) Способ получения производных 2-(((5-1r-2-r-1,3-тиазол-4-ил)метил)сульфанил)-1,3-бензимидазола-2r

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)